Approval · Notice of Compliance 30343 · 2023
CERTICAN: Notice of Compliance 30343
Issued March 17, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30343
- Date
- March 17, 2023
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Design update to the mock-up labels.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CERTICAN | Not yet assigned | — |
Medicinal ingredients
- EVEROLIMUS 0.25 MG per TAB
- EVEROLIMUS 0.5 MG per TAB
- EVEROLIMUS 0.75 MG per TAB